The targeting DNA repair drugs market encompasses a specialized segment of oncology and genetic disorder therapeutics focused on modulating DNA repair mechanisms. These drugs are designed to either inhibit or enhance the cell's natural ability to repair DNA damage, depending on the therapeutic goal. Most commonly used in cancer treatment, they exploit the defective DNA repair pathways in cancer cells to increase their vulnerability to treatments like chemotherapy, radiation, and immunotherapy. By selectively targeting repair pathways such as homologous recombination (HR) or base excision repair (BER), these drugs offer a precision medicine approach to cancer therapy.

Bio-Based Nutraceuticals Market Size Was Valued at USD 51.91 Billion in 2024 and is Projected to Reach USD 85.59 Billion by 2032, Growing at a CAGR of 6.45% From 2024-2032.